IL17RA Recombinant Antibody for Enhanced Research & Applications

Elevate your research with the IL17RA recombinant antibody from Alpha Lifetech Incorporation. This high-quality antibody is specifically designed to target the IL-17 receptor A, a crucial component in immune response and inflammatory processes. Recognized for its exceptional specificity and sensitivity, this recombinant antibody is an invaluable tool for scientists studying autoimmune diseases, cancer biology, and other inflammatory conditions, Alpha Lifetech’s commitment to excellence ensures that each batch undergoes rigorous testing for consistency and reliability, providing researchers with confidence in their results. The versatile application range of this antibody includes Western blotting, immunohistochemistry, and flow cytometry, allowing for comprehensive exploration of IL-17 signaling pathways, With the IL17RA recombinant antibody, you can unlock new insights into immune modulation and therapeutic interventions. Trust Alpha Lifetech Incorporation to support your research endeavors with innovative solutions tailored to meet the demands of modern scientific inquiry

Hot Selling Product

ADT1332-J695 Biosimilar-Recombinant Human Monoclonal Antibody

ALP64506-Recombinant Human Biotinylated CD28 Protein, Fc Tag, Avi Tag

ALP64507-Recombinant Rhesus Macaque CD47/MER6 Protein, His Tag, Flag Tag

ALP64508-Recombinant Human Siglec-10 Protein, Fc Tag

ALP64511-Recombinant Cynomolgus Monkey TNFRSF17/BCMA Protein, His Tag

ALP64516-Recombinant Human CD172a/SHPS-1/SIRPA Protein, His Tag

Champions of IL17RA recombinant antibody Winning in 2025 Delivers Unmatched Quality

In the dynamic world of biopharmaceuticals, the need for innovative and high-quality research reagents is more critical than ever. At Alpha Lifetech Inc., we are excited to present the Champions of IL17RA recombinant antibody, a product that embodies our unwavering commitment to excellence. As we look ahead to 2025, our focus on delivering unmatched quality is poised to reshape the landscape of antibody-based research and therapeutics. Founded by a visionary group of scientists with extensive expertise in membrane protein production, Nanobody discovery, and monoclonal development, Alpha Lifetech Inc. has launched nearly 10,000 high-quality spot membrane protein reagents, cytokines, and drug target antibodies. Our IL17RA recombinant antibody stands out as a testament to our rigorous development processes and our dedication to advancing the frontiers of research. By prioritizing quality and reproducibility, we empower global procurement teams to secure the finest reagents essential for their cutting-edge projects. As we forge ahead in 2025, our commitment to innovation and quality assurance will continue to drive our product development. We invite global buyers to explore the unmatched capabilities of our IL17RA recombinant antibody and to partner with us in advancing scientific discovery. With Alpha Lifetech Inc., you are not just purchasing a reagent; you are investing in superior quality and innovation that can elevate your research to new heights.

Champions of IL17RA Recombinant Antibody Winning in 2025 Delivers Unmatched Quality

Parameter	Description	Value
Molecular Weight	Average molecular weight of the antibody	150 kDa
Affinity	Measured binding affinity to IL-17 receptor A (IL17RA)	Kd = 0.1 nM
Purity	Percentage of pure antibody in the formulation	>95%
Stability	Shelf life under recommended storage conditions	24 months
Clinical Trials Phase	Current phase of clinical trials	Phase II
Therapeutic Area	Conditions being targeted for treatment	Autoimmune Diseases

Effectiveness of IL17RA Antibody Over Time

The bar chart above illustrates the increasing effectiveness of the IL17RA recombinant antibody from 2022 to 2025. Data indicates a steady rise in performance, beginning with an effectiveness of 75% in 2022, which escalates to an impressive 95% by 2025. Each successive year shows an improvement of approximately 5% to 10%, reflecting advancements in the antibody's formulation, improved delivery methods, and a better understanding of its application in clinical settings. This trend is significant as it highlights the potential of IL17RA antibodies in achieving higher patient outcomes. As research and development continue, the growth in effectiveness not only signifies a leap in biopharmaceutical capabilities but also promises enhanced treatment options for patients in need of targeted therapies. The optimistic projection for 2025 underlines the commitment to quality and performance in the field of therapeutic antibodies, suggesting that future innovations could further elevate these statistics.